HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombomodulin Protects Against Bacterial Keratitis, Is Anti-Inflammatory, but Not Angiogenic.

AbstractPURPOSE:
Thrombomodulin (TM) is a multidomain, transmembrane protein with anti-inflammatory properties. Thrombomodulin domain (D) 1 is lectin-like, interacting with Lewis Y antigen on lipopolysaccharide, and with HMGB1, while TMD23 is associated with angiogenic and anti-inflammatory functions. Thus, we tested if TM is protective against Pseudomonas aeruginosa keratitis and whether it enhanced corneal vascularity.
METHODS:
Eyes of C57BL/6 (B6) mice were injected with recombinant TM (rTM), rTMD1, or PBS subconjunctivally before and intraperitoneally after infection with P. aeruginosa. Clinical scores, photography with a slit lamp, RT-PCR, ELISA, myeloperoxidase (MPO) assay, viable bacterial plate counts, and India ink perfusion were used to assess the disease response and corneal vascularity (rTM only).
RESULTS:
Recombinant TM versus PBS treatment reduced clinical scores and corneal opacity. Corneal mRNA levels for HMGB1 were unchanged, but proinflammatory molecules IL-1β, CXCL2, NF-κB, TLR4, and RAGE were decreased; anti-inflammatory molecules SIGIRR and ST2 were increased. ELISA confirmed the mRNA data for HMGB1, IL-1β, and CXCL2 proteins. Both neutrophil influx and viable bacterial plate counts also were decreased after rTM treatment. Protein levels for angiogenic molecules VEGF, VEGFR-1, and VEGFR-2 were measured at 5 days post infection and were not different or reduced significantly after rTM treatment. Further, perfusion with India ink revealed similar vessel ingrowth between the two groups. Similar studies were performed with rTMD1, but disease severity, mRNA, proteins, MPO, and plate counts were not changed from controls.
CONCLUSIONS:
These data provide evidence that rTM treatment is protective against bacterial keratitis, does not reduce HMGB1, and is not angiogenic.
AuthorsSharon A McClellan, Sandamali A Ekanayaka, Cui Li, Xiaoyu Jiang, Ronald P Barrett, Linda D Hazlett
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 56 Issue 13 Pg. 8091-100 (Dec 2015) ISSN: 1552-5783 [Electronic] United States
PMID26720461 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Cytokines
  • NF-kappa B
  • Protective Agents
  • RNA, Messenger
  • Thrombomodulin
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2
Topics
  • Animals
  • Anti-Inflammatory Agents (therapeutic use)
  • Colony Count, Microbial
  • Cornea (metabolism)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Eye Infections, Bacterial (drug therapy, microbiology, pathology)
  • Keratitis (drug therapy, microbiology, pathology)
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B (metabolism)
  • Neutrophils (physiology)
  • Protective Agents (therapeutic use)
  • Pseudomonas Infections (drug therapy, microbiology, pathology)
  • Pseudomonas aeruginosa
  • RNA, Messenger (metabolism)
  • Thrombomodulin (therapeutic use)
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: